Healthcare Industry News: leg attack
News Release - November 6, 2006
Nuvelo Announces Presentations on Alfimeprase and rNAPc2 at The American Heart Association Scientific Sessions 2006
SAN CARLOS, Calif., Nov. 6 (HSMN NewsFeed) -- Nuvelo, Inc. (Nasdaq: NUVO ) today announced that clinical data from two Phase 2 trials, the NAPA-1 (Novel Arterial Perfusion with Alfimeprase) trial evaluating alfimeprase in patients with acute peripheral arterial occlusion (PAO), or "leg attack," and the ANTHEM (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 trial looking at recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with acute coronary syndromes (ACS), will be presented in poster presentations at the American Heart Association (AHA) Scientific Sessions 2006 taking place at McCormick Place in Chicago, IL, November 12-15, 2006.
The presentation details are as follows:
Date/Time: Monday, November 13, 2006, 9:30 - 11:00 a.m. CT
Poster Session (Abstract #2263/C18): F1.2 correlates with ischemia by
Holter monitoring and is suppressed by rNAPc2: an ANTHEM - TIMI 32
biomarker analysis
Date/Time: Tuesday, November 14, 2006, 9:30 - 11:00 a.m. CT
Poster Session (Abstract #2777/C240): Alfimeprase, a Novel Direct-Acting
Fibrinolytic Agent in Acute Peripheral Arterial Occlusion: Report of a
Phase 2, Multi-Center, Open-Label, Dose-Defining Study (NAPA-1)
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic in Phase 3 clinical trials for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical procedures. Nuvelo is also advancing an emerging oncology pipeline, which includes NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis, inflammatory bowel disease and short bowel syndrome as well as rNAPc2 for potential use as a cancer therapy. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
This press release contains "forward-looking statements" regarding the timing and progress of Nuvelo's clinical programs and the potential improvement or benefit that current and future clinical trial programs may demonstrate which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward- looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; the impact of competitive products and technological changes; uncertainties relating to patent protection and uncertainties relating to our ability to obtain funding. These and other factors are identified and described in more detail in Nuvelo filings with the SEC, including without limitation Nuvelo's Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.
Source: Nuvelo
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
